Oncology Grand Rounds Series: Part 5 — Gynecologic Cancers (Webinar Audio Proceedings)

Submitted by web@researchtop... on Wed, 07/29/2020 - 16:42

Listen to streaming audioright from your computer
Download programto your desktop
Subscribe to podcastto have this and future issues delivered to your iTunes library

Audio Highlights

Topic 1:	Introduction
Topic 2:	Mechanism of action of PARP inhibitors and integration into the therapeutic algorithm for patients with advanced ovarian cancer (OC)
Topic 3:	Efficacy and duration of maintenance therapy with olaparib or niraparib in the Phase III SOLO-1 and PRIMA trials for patients with OC in the first-line setting
Topic 4:	Response and tolerability with olaparib as maintenance therapy for patients with advanced OC with BRCA mutations
Topic 5:	Genetic testing for patients with OC; selection of PARP inhibitor therapy
Topic 6:	Choice of PARP inhibitor alone or in combination with bevacizumab as maintenance therapy for patients with advanced OC
Topic 7:	Activity of olaparib as maintenance therapy for OC; gastrointestinal and hematologic toxicities with PARP inhibitors
Topic 8:	Role of immune checkpoint inhibitors in the treatment of endometrial cancer; significance of microsatellite instability
Topic 9:	Emerging data with pembrolizumab alone or in combination with lenvatinib for endometrial cancer
Topic 10:	Dosing considerations and side effects with pembrolizumab/lenvatinib
Topic 11:	Response to immune checkpoint inhibitors in patients with cervical cancer
Topic 12:	Immune-related adverse events associated with checkpoint inhibitors; considerations for the use of immune checkpoint inhibitors in the COVID-19 era

FACULTY

Paula J Anastasia, RN, MN, AOCN
Gyn-Oncology Clinical Nurse Specialist
UCLA Medical Center
David Geffen School of Medicine
Los Angeles, California

Jennifer Filipi, MSN, NP
Massachusetts General Hospital
Center for Gynecologic Oncology
Boston, Massachusetts

David M O’Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
The Ohio State University and The James Cancer Center
Columbus, Ohio

Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

MODERATOR

Neil Love, MD
Research To Practice
Miami, Florida